Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo's next-generation weight loss drug, cagrisema, has disappointed once again with lower-than-expected weight loss results. The latest data showed only a 15.7% weight loss in patients with diabetes after 68 weeks, below the company's projections. This news has caused Novo's stock to dip. Additionally, side effects associated with GLP-1-based obesity drugs are turning patients away from this type of treatment. Despite efforts to mitigate these side effects, studies show that various factors are causing patients to discontinue treatment.In other news, Johnson & Johnson's oral IL-23R blocker has set a new standard in plaque psoriasis treatment, outperforming Bristol Myers Squibb's Sotyktu. BMS's Sotyktu did, however, notch a phase III win in psoriatic arthritis. Novo is also conducting studies on GLP-1s for addiction, limited to ongoing phase II trials. Overall, the landscape of weight loss and skin condition treatments is evolving, with new drugs showing promise and competition heating up in the market.Drugmakers are focusing on reducing the side effects of GLP-1-based obesity drugs to address high discontinuation rates among patients. Novavax is applying lessons learned from the COVID-19 pandemic as it looks towards developing other novel vaccines. The FDA faces a challenging decision on biomarker-based label restrictions for certain cancer drugs, while J&J has axed a late-stage depression trial due to underwhelming efficacy.Other news includes AstraZeneca's positive data on Imfinzi for stomach cancer and Takeda's drug reducing the need for blood withdrawals in clinical trials. Novavax is also working with pharma partners to bring new vaccines to market. The FDA is dealing with staff and site turnover, and more job opportunities in the biopharma industry are available.Readers are encouraged to provide feedback on what topics they would like to see covered in future articles.